Table 4 Comparison between group 1 (pts received viral vector-based vaccines with adverse events) vs group 3 (pts received inactivated virus-based vaccines with adverse events)
Group 1 (viral vector vaccine) | Percentage | Group 3 (inactivated virus vaccine) | Percentage | DIFF/95 CI/chi-squared/DF/significance | |
|---|---|---|---|---|---|
Thrombosis/thrombocytopenia | 236 | 51.30% | 0 | 0% | 51.3%/46.6659–55.8379%/317.046/1/p < 0.0001 |
ICH | 33 | 7% | 0 | 0% | 7%/4.8418–9.7052%/33.332/1/p < 0.0001 |
DIC | 5 | 1% | 0 | 0% | 1%/− 0.0148–2.3981%/4.618/1/p = 0.0316 |
GBS | 16 | 4% | 0 | 0% | 4%/2.3366–6.2045%/18.755/1//p < 0.0001 |
Acute TM | 7 | 2% | 1 | 0.20% | 1.8%/0.4357–3.5402%/6.842/1/p = 0.0089 |
Acute demyelinating polyradiculopathy | 2 | 0.40% | 0 | 0% | .4%/− 0.4793–1.5170%/1.842/1/p = 0.1748 |
Acute disseminated encephalomyelitis | 1 | 0.20% | 0 | 0% | .2%/−0.6448–1.1916%/0.920/1/p = 0.3375 |
Inflammatory myositis | 3 | 0.60% | 0 | 0% | .6%/− 0.3215–1.8223%/2.765/1/p = 0.0963 |
Erythema nodosum | 1 | 0.20% | 0 | 0% | 0.2%/− 0.6448–1.1916%/0.920/1/p = 0.3375 |
Renal complication | 3 | 0.60% | 1 | 0.20% | .4%/− 0.6708–1.6336%/0.923/1/p = 0.3368 |
Acute macular neuroretinopathy/facial palsy/choroiditis | 7 | 2% | 1 | 0.20% | 1.8%/0.4357–3.5402%/6.842/1/p = 0.0089 |
Cutaneous vasculitis | 0 | 0.00% | 0 | 0% | 0%/− 0.8282–0.8282% |
Myocarditis | 0 | 0.00% | 0 | 0% | 0%/− 0.8282–0.8282% |
Acute myocardial infarction | 0 | 0.00% | 0 | 0% | 0%/− 0.8282–0.8282% |
ITP | 0 | 0.00% | 0 | 0% | 0%/− 0.8282–0.8282% |
Miller Fisher S | 0 | 0.00% | 0 | 0% | 0%/− 0.8282–0.8282% |
Sarcoid reaction | 0 | 0.00% | 0 | 0% | 0%/− 0.8282–0.8282% |
Steven Johnson Syndrome | 0 | 0.00% | 0 | 0% | 0%/− 0.8282–0.8282% |
Uveitis | 0 | 0.00% | 1 | 0.20% | .2%/− 0.6448–1.1916%/0.920/1/P = 0.3375 |